Sugi Predict

Sugi Predict / Compounds / SCHEMBL25253974

SCHEMBL25253974

SCHEMBL25253974

C=CC(=O)Nc1cccc2c1CN(C(=O)c1c(O)cc(O)cc1OCc1ccccc1)C2

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 7/20 0.39
▸ TGM1 P22735 5/20 0.39
▸ F13A1 P00488 4/20 0.39
▸ TGM3 Q08188 1/20 0.39
▸ BTK Q06187 5/20 0.37
▸ HSP90B1 P14625 2/20 0.37
▸ TRAP1 Q12931 2/20 0.37
▸ FGFR1 P11362 2/20 0.36
▸ SRC P12931 2/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ SLC5A1 P13866 1/20 0.36
▸ SLC5A2 P31639 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ ERBB2 P04626 1/20 0.35
▸ NAMPT P43490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30970470 1.00 TGM2 (0.39) TGM2TGM1F13A1TGM3BTK
SCHEMBL29168554 0.89 BRD4 (0.49) HSP90B1TRAP1BRD4
SCHEMBL30970478 0.88 TRAP1 (0.36) HSP90B1TRAP1BRD4SLC5A1SLC5A2
SCHEMBL25248972 0.88 TRAP1 (0.36) HSP90B1TRAP1BRD4SLC5A1SLC5A2
SCHEMBL24913934 0.87 TRAP1 (0.41) HSP90B1TRAP1BRD4SLC5A1SLC5A2
SCHEMBL30789151 0.87 TRAP1 (0.41) HSP90B1TRAP1BRD4SLC5A1SLC5A2
SCHEMBL25212259 0.86 TGM2 (0.37) TGM2TGM1F13A1TGM3BTK
SCHEMBL30970494 0.86 TGM2 (0.37) TGM2TGM1F13A1TGM3BTK
SCHEMBL25255911 0.86 BTK (0.42) BTKEGFRERBB2
SCHEMBL30378187 0.86 BTK (0.42) BTKEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425453-A1 ISOINDOLINES AS PMS2 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2024-12-26 — — US claimed
EP-4441031-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2024-10-09 — — EP claimed
CN-118317949-A Isoindolines as PMS2 inhibitors 奈奥芬莱有限公司 2024-07-09 — — CN claimed
WO-2023094834-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2023-06-01 — — WO claimed
US-20240425453-A1 ISOINDOLINES AS PMS2 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2024-12-26 — — US disclosed
EP-4441031-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2024-10-09 — — EP disclosed
CN-118317949-A Isoindolines as PMS2 inhibitors 奈奥芬莱有限公司 2024-07-09 — — CN disclosed
WO-2023094834-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2023-06-01 — — WO disclosed
WO-2023094834-A1 ISOINDOLINES AS PMS2 INHIBITORS Neophore Limited (GB) 2023-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425453-A1 ISOINDOLINES AS PMS2 INHIBITORS PMS2, MSH2, RECQL TGM2 3167/4885TGM1 3723/4885F13A1 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.